FDA Approves Second Geographic Atrophy Drug, Setting Stage for Astellas and Iveric Bio Showdown
TL;DR Summary
The FDA has approved Iveric Bio's geographic atrophy treatment, making it the second drug to be cleared for a leading cause of blindness. Iveric Bio will launch the treatment, called Izervay, in the coming weeks at a cost of $2,100 per single-dose vial. This approval strengthens the case for Astellas' recent acquisition of Iveric Bio and follows a previous approval for competitor Apellis.
- FDA approves second geographic atrophy drug but caps use period, as Astellas' Iveric looks to spar with Apellis Endpoints News
- FDA signs off on Astellas' recently acquired GA drug Izervay FiercePharma
- Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy PR Newswire
- BREAKING NEWS: FDA approves Iveric Bio's avacincaptad pegol intravitreal solution for treatment of geographic atrophy Modern Retina
- Astellas Pharma Secures US FDA Approval for Izervay BNN Bloomberg
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
51%
129 → 63 words
Want the full story? Read the original article
Read on Endpoints News